HRAS and neoplasm: In the EP group, 12 tumours had pathogenic mutations in key genes associated with response to anti‐EGFR therapy (1 × in BRAF + PTEN, 1 × in BRAF + PIK3CA, 2 × in BRAF, 3 × in PTEN, 2 × in NRAS, 1 × in KRAS, 1 × in HRAS and 1 × in PIK3CA).